Marlon Perera

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “From Concept to Regulatory Drug Approval: Lessons for Theranostics”.

From Concept to Regulatory Drug Approval: Lessons for Theranostics

Journal of Nuclear Medicine(2022)10.2967/jnumed.121.263301

N/A

0.851DataRank · unranked

24 citations

Michael J. Morris, Marlon Perera

Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer

Frontiers in Oncology(2022)10.3389/fonc.2022.929444

N/A

0.434DataRank · unranked

17 citations

Arthur Yim, Nathan Papa, Shankar Siva, Joseph Ischia, Karim Touijer +4 more

Oncologic outcomes of patients with lymph node invasion at prostatectomy and post-prostatectomy biochemical persistence

Urologic Oncology Seminars and Original Investigations(2022)10.1016/j.urolonc.2022.10.021

N/A

0.431DataRank · unranked

5 citations

Souhil Lebdai, Amy L. Tin, Daniel D. Sjoberg, Nicole Benfante, Benjamin Beech +9 more

Gene expression of prostate-specific membrane antigen (FOLH1) in clear cell renal cell carcinoma predicts angiogenesis and response to tyrosine kinase inhibitors

Urologic Oncology Seminars and Original Investigations(2024)10.1016/j.urolonc.2024.10.013

N/A

0.331DataRank · unranked

6 citations

Marlon Perera, Nathan Papa, Fengshen Kuo, Mahdi Golkaram, Phillip M. Rappold +7 more

A decade of declining prostatectomy margin positivity within a prostate cancer clinical quality registry

Urologic Oncology Seminars and Original Investigations(2022)10.1016/j.urolonc.2022.08.012

N/A

0DataRank · unranked

6 citations

Marlon Perera, Jonathan G. Bensley, Melanie Evans, Jeremy Millar, Mark Frydenberg +3 more

Outcomes of Grade Group 2 and 3 Prostate Cancer on Initial Versus Confirmatory Biopsy: Implications for Active Surveillance

European Urology Focus(2022)10.1016/j.euf.2022.12.008

N/A

0DataRank · unranked

9 citations

Ghalib Jibara, Amy L. Tin, Samuel Haywood, Daniel D. Sjoberg, Nicole Benfante +9 more

Point-Counterpoint: Radioisotope-guided Lymphadenectomy for Pelvic Node Staging: The SENTINELLE Study

The Journal of Urology(2023)10.1097/ju.0000000000003494

N/A

0DataRank · unranked

1 citations

Karim Touijer, Marlon Perera

Quantification of Gleason Pattern 4 Metrics Identifies Pathologic Progression in Patients With Grade Group 2 Prostate Cancer on Active Surveillance

Clinical Genitourinary Cancer(2024)10.1016/j.clgc.2024.102204

N/A

0DataRank · unranked

8 citations

Melissa Assel, Sunny Nalavenkata, Sari Khaleel, Nicole Benfante, Sigrid Carlsson +9 more